Immunolabs.com

Site Inspections

Overview & More informations

Immunolabs is a privately held biotechnology company based in Toronto, Canada that focuses on the discovery and development of novel antibody therapeutics. The company was founded in 2012 by a team of scientists from the University of Toronto and the Ontario Institute for Cancer Research. Immunolabs' mission is to develop innovative antibody-based therapies that can improve the lives of patients with cancer and other serious diseases.

The company's proprietary antibody discovery platform, called the ATLAS (Antibody Therapeutic Library and Screening) platform, enables the rapid identification and characterization of novel antibody candidates. The ATLAS platform is based on a library of over 100 billion unique antibody sequences, which allows Immunolabs to screen a vast repertoire of antibodies for those that bind to specific targets of interest. The platform also includes a suite of high-throughput screening assays that can be used to assess the efficacy and specificity of antibody candidates.

Immunolabs has a pipeline of several antibody therapeutics in development, including:

* **IL-8R antibody:** This antibody is designed to block the interleukin-8 receptor (IL-8R), which is expressed on a variety of cancer cells. IL-8R signaling has been shown to promote tumor growth, angiogenesis, and invasion. By blocking IL-8R, this antibody is expected to inhibit tumor growth and metastasis.
* **PD-1 antibody:** This antibody is designed to block the programmed cell death protein 1 (PD-1), which is expressed on T cells. PD-1 signaling has been shown to inhibit T cell activation and cytotoxicity, which can lead to tumor immune evasion. By blocking PD-1, this antibody is expected to enhance T cell function and promote tumor regression.
* **CTLA-4 antibody:** This antibody is designed to block the cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which is expressed on T cells. CTLA-4 signaling has been shown to inhibit T cell activation and cytotoxicity, which can lead to tumor immune evasion. By blocking CTLA-4, this antibody is expected to enhance T cell function and promote tumor regression.

Immunolabs is also developing a number of other antibody therapeutics for the treatment of cancer, autoimmune diseases, and other serious diseases. The company has a strong track record of innovation and is well-positioned to continue to develop novel antibody-based therapies that can improve the lives of patients.

Domains Expiration Date Updated